Patents by Inventor Adam James Davenport

Adam James Davenport has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Carboxylic acid aromatic amides
    Patent number: 12023319
    Abstract: The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: July 2, 2024
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Stefan Bäurle, Adam James Davenport, Christopher Stimson, Jens Nagel, Nicole Schmidt, Andrea Rotgeri, Ina Gröticke, Alexandra Rausch, Juergen Klar, Thomas Dyrks
  • Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor
    Patent number: 11905270
    Abstract: The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a diseaseas a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: February 20, 2024
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Stefan Baeurle, Adam James Davenport, Christopher Stimson, Jens Nagel, Nicole Schmidt, Andrea Rotgeri, Ina Groeticke, Alexandra Rausch, Juergen Klar, Thomas Dyrks
  • Novel compounds for treatment of diseases related to DUX4 expression
    Publication number: 20230271953
    Abstract: The present invention relates to compounds that act as DUX4 repressors, suitable for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.
    Type: Application
    Filed: November 27, 2020
    Publication date: August 31, 2023
    Applicant: Facio Intellectual Property B.V.
    Inventors: Pui Leng Loke, Joris Herman De Maeyer, Robert David Matthew Pace, Simon Fletcher Elwood, Gregory Foulkes, Andrew Anighoro, Ainoa Rueda-Zubiaurre, Jonathan Philip Richards, Adam James Davenport, Cristina Lecci, Anthony Paul Dickie, Gerd Schnorrenberg
  • CARBOXYLIC ACID AROMATIC AMIDES
    Publication number: 20230086179
    Abstract: The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: December 18, 2017
    Publication date: March 23, 2023
    Inventors: Stefan BAEURLE, Adam James DAVENPORT, Christopher STIMSON, Jens NAGEL, Nicole SCHMIDT, Andrea ROTGERI, Ina GROETICKE, Alexandra RAUSCH, Juergen KLAR, Thomas DYRKS
  • 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES
    Publication number: 20230053411
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: September 9, 2021
    Publication date: February 23, 2023
    Applicant: Bayer Aktiengesellschaft
    Inventors: Adam James DAVENPORT, Nico BRÄUER, Oliver Martin FISCHER, Andrea ROTGERI, Antje ROTTMANN, Ioana NEAGOE, Jens NAGEL, Anne-Marie GODINHO-COELHO, Jürgen KLAR
  • New compounds for treatment of diseases related to DUX4 expression
    Publication number: 20230052017
    Abstract: The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.
    Type: Application
    Filed: November 27, 2020
    Publication date: February 16, 2023
    Applicant: Facio Intellectual Property B.V.
    Inventors: Pui Leng Loke, Joris Herman De Maeyer, Robert David Matthew Pace, Gregory Foulkes, Ainoa Rueda-Zubiaurre, Simon Fletcher Ellwood, Adam James Davenport, Anthony Paul Dickie, Gerd Schnorrenberg
  • CARBOXYLIC ACID AROMATIC AMIDES
    Publication number: 20230043209
    Abstract: The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: September 17, 2021
    Publication date: February 9, 2023
    Inventors: Stefan BAEURLE, Adam James DAVENPORT, Christopher STIMSON, Jens NAGEL, Nicole SCHMIDT, Andrea ROTGERI, Ina GROETICKE, Alexandra RAUSCH, Juergen KLAR, Thomas DYRKS
  • Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors
    Patent number: 11319324
    Abstract: The present invention covers substituted. Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: May 3, 2022
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Marcus Koppitz, Holger Siebeneicher, Nico Bräuer, Elisabeth Pook, Andrea Rotgeri, Roland Neuhaus, Oliver Martin Fischer, Jens Nagel, Adam James Davenport, James Lindsay Carr, Robert James Townsend, Nina Connelly Ursinyova, Shelley Anne Parrott
  • NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS
    Publication number: 20210317128
    Abstract: The present invention covers substituted. Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: October 18, 2018
    Publication date: October 14, 2021
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Marcus KOPPITZ, Holger SIEBENEICHER, Nico BRÄUER, Elisabeth POOK, Andrea ROTGERI, Roland NEUHAUS, Oliver Martin FISCHER, Jens NAGEL, Adam James DAVENPORT, James Lindsay CARR, Robert James TOWNSEND, Nina CONNELLY URSINYOVA, Shelley Anne PARROTT
  • TETRAZOLE CONTAINING COMPOUNDS
    Publication number: 20210317092
    Abstract: The present invention relates to tetrazole containing compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease syndrome, condition, or symptoms, in particular related to chronic pain and inflammation, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: December 18, 2017
    Publication date: October 14, 2021
    Inventors: Stefan BÄEURLE, Adam James DAVENPORT, Christopher STIMSON, James Lindsay CARR, Christian Abingdon BUBERT, Frédéric Jacques MARLIN, Jens NAGEL, Nicole SCHMIDT, Andrea ROTGERI, Horst IRLBACHER
  • 1,3-thiazol-2-yl substituted benzamides
    Patent number: 11142523
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: October 12, 2021
    Assignee: Bayer Aktiengesellschaft
    Inventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
  • 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES
    Publication number: 20200131169
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: October 1, 2019
    Publication date: April 30, 2020
    Applicant: Bayer Aktiengesellschaft
    Inventors: Adam James DAVENPORT, Nico BRÄUER, Oliver Martin FISCHER, Andrea ROTGERI, Antje ROTTMANN, Ioana NEAGOE, Jens NAGEL, Anne-Marie GODINHO-COELHO, Jürgen KLAR
  • KCNQ2-5 channel activator
    Patent number: 10519105
    Abstract: An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (I) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (I) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like).
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: December 31, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kentaro Yashiro, Masashi Kato, Tetsuji Saito, Takuya Okada, Daisuke Wakamatsu, Adam James Davenport, Christopher Charles Stimson
  • 1,3-thiazol-2-yl substituted benzamides
    Patent number: 10472354
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: November 12, 2019
    Assignee: Bayer Aktiengesellschaft
    Inventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
  • TETRAZOLE-CONTAINING 1,2-CYCLOPROPANE-CARBOXAMIDES
    Publication number: 20190194148
    Abstract: The present invention relates to N-(tetrazolylaryl) amide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 27, 2019
    Inventors: Stefan Bäurle, Jens Nagel, Andrea Rotgeri, Adam James Davenport, Christopher Charles Stimson
  • 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES
    Publication number: 20190185466
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: November 15, 2018
    Publication date: June 20, 2019
    Applicant: Bayer Aktiengesellschaft
    Inventors: Adam James DAVENPORT, Nico BRÄUER, Oliver Martin FISCHER, Andrea ROTGERI, Antje ROTTMANN, Ioana NEAGOE, Jens NAGEL, Anne-Marie GODINHO-COELHO, Jürgen KLAR
  • TETRAZOLYL-CONTAINING CYCLOPROPANECARBOXAMIDES
    Publication number: 20190177284
    Abstract: The present invention relates to tetrazolyl-containing cyclopropanecarboxamides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 13, 2019
    Inventors: Stefan Bäurle, Jens Nagel, Andrea Rotgeri, Adam James Davenport, Christopher Charles Stimson
  • CARBOXYLIC ACID AROMATIC 1,2-CYCLOPROPYLAMIDES
    Publication number: 20190177279
    Abstract: The present invention relates to carboxylic acid aromatic 1,2-cyclopropylamides of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 13, 2019
    Inventors: Stefan Bäurle, Jens Nagel, Andrea Rotgeri, Adam James Davenport, Christopher Charles Stimson
  • KCNQ2-5 CHANNEL ACTIVATOR
    Publication number: 20190127320
    Abstract: An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (1) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (1) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like).
    Type: Application
    Filed: April 21, 2017
    Publication date: May 2, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kentaro YASHIRO, Masashi KATO, Tetsuji SAITO, Takuya OKADA, Daisuke WAKAMATSU, Adam James DAVENPORT, Christopher Charles STIMSON
  • 1,3-thiazol-2-yl substituted benzamides
    Patent number: 10202369
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: February 12, 2019
    Assignee: Bayer Aktiengesellschaft
    Inventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar